Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
  • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2013—Organic compounds, e.g. phospholipids, fats
  • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• the present application relates to a complex of sitagliptin (4-oxo-4-[3-(trifluroromethyl)- 5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H ⁇ ) and tannic acid (“sitagliptin tannate complex”), which is a potent inhibitor of dipeptidyl peptidase-IV (“DPP-IV").
• DPP-IV dipeptidyl peptidase-IV
• This invention further relates to an oral dosage form comprising an effective amount of the sitagliptin tannate complex, a pharmaceutical intermediate comprising an effective amount of the sitagliptin tannate complex, methods of treating, controlling or preventing a disease or condition for which a DPP-IV inhibitor is indicated by administering an effective amount of the sitagliptin tannate complex to a patient in need thereof, and a process to prepare the sitagliptin tannate complex.
• DPP-IV glucose-dependent insulinotropic peptide
• GLP-1 glucose-dependent insulinotropic peptide 1
• NIDDM non-insulin dependent diabetes mellitus
• WO2003/004498 assigned to Merck Sharp & Dohme Corp., describes a class of beta- amino tetrahydrotriazolo[4,3-a]pyrazines, which are potent inhibitors of DPP-IV, and therefore are useful for the treatment of type 2 diabetes.
• WO 03/004498 is 4-oxo- 4-[3-(trifluoromethyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-l-(2,4,5- trifluorophenyl)butan-2-amine. While pharmaceutically acceptable salts of this compound are generically encompassed within the scope of WO 03/004498, there is no specific disclosure the sitagliptin tannate complex.
• dihydrogenphosphonate salt is a potent inhibitor of DPP-IV and, therefore, is useful for the treatment and prevention of non-insulin dependent diabetes mellitus, also referred to as type 2 diabetes, obesity and high blood pressure.
• WO2005/003135 also describes a crystalline monohydrate of the dihydrogenphosphate salt as well as a process for its preparation,
• WO2005/003135 does not describe a sitagliptin tannate complex.
• Tannic acid also known as tannin, gallotannin, glycerite or gallotannin, is a yellowish to light brown amorphous powder having the approximate composition of C76H52O46 and a molecular weight of about 1701 grams/mol.
• tannic acid is typically produced from Turkish or Chinese nutgall, it can be derived from the bark and fruit of many plants. Tannic acid is very soluble in water, glycerin or alcohol. Tannic acid may be obtained either by extraction from natural products or through synthetic chemical synthesis.
• Tannate complexes comprising pharmaceutically active compounds are known in the art. See, e.g., US 5,663,415; US 6,881,741 B2; US 6,939,856 B2; US 6,670,370 Bl; and US
• Tannate salts have been found to have better organoleptic properties, such as taste, in comparison to other salts or free base forms. See, e.g., US 2005/0202050 Al or US
• Sitagliptin as a monohydrate phosphate salt is the active ingredient in JANUVIA ® and one of the active agents in JANUMET ® AND JANUMET XR ® , all marketed by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., to improve glycemic control in adults with type 2 diabetes mellitus.
• An unintended effect of sitagliptin monohydrate phosphate is that it has an intense, lingering bitter taste.
• drug products containing sitagliptin monohydrate phosphate are formulated as a film-coated tablet. Marketing sitagliptin monohydrate phosphate as a film-coated tablet is not always ideal as an estimated 20% of the patients taking JANUMET ® experience a difficulty in swallowing the tablet.
• any of these alternative intra-oral dosage forms must be relatively easy to
• the present invention is directed to a tannate complex of sitagliptin, to an oral dosage form comprising an effective amount of the sitagliptin tannate complex, a pharmaceutical intermediate comprising an effective amount of the sitagliptin tannate complex, and to methods of treating, controlling, or preventing a disease or condition for which a DPP-IV inhibitor is indicated by administering an effective amount of the sitagliptin tannate complex to a patient in need thereof.
• This invention further relates to processes to prepare the sitagliptin tannate complex.
• the sitagliptin tannate complex possesses a release property or profile in which the sitagliptin tannate complex exhibits a negligible release rate at neutral pH, such as that found in the mouth, and immediate release in acidic pH, such as that found in the stomach.
• This release property allows one to formulate sitagliptin in oral dosage form that is easier to swallow and does not need a film layer, e.g., a dosage form such as a chewable tablet, soft chew, medicated gum or disintegrating table, because the sitagliptin tannate complex has a neutral taste in the mouth.
• oral dosage forms that have a neutral taste would be expected to improve patient compliance in taking the medicine.
• tannate complexes impart extended release properties to a pharmaceutical formulation comprising an active pharmaceutical ingredient (API) (see, e.g., US 6,670,370 and US 6,939,856).
• API active pharmaceutical ingredient
• Exhibiting extended release properties implies that the API in an extended release pharmaceutical formulation is stable (i.e., exhibits negligible dissociation) in acidic pH, such as that found in the stomach, and dissociates in a predefined manner over time in neutral pH, such as that found in the intestine.
• the release property of the inventive sitagliptin tannate complex unexpectedly the opposite occurs in that the immediate release occurs at acidic pH.
• FIG. 1 is graph depicting the two-stage dissolution profile for the sitagliptin tannate complex of Example 1. The graph plots the percentage (%) of sitagliptin released from the sitagliptin tannate complex versus time.
• FIG. 2 is a graph depicting the two-stage dissolution profile for the sitagliptin tannate complex of Example 2. The graph plots the percentage (%) of sitagliptin released from the sitagliptin tannate complex versus time.
• FIG. 3 is a graph depicting the two-stage dissolution profile for a soft-chew formulation comprising the sitagliptin tannate complex of Example 3. The graph plots the percentage (%) of sitagliptin released from the sitagliptin tannate complex in the soft-chew formulation versus time.
• this invention provides for a sitagliptin tannate complex.
• sitagliptin tannate complex wherein the sitagliptin content is between about 25% and about 75% by weight or between about 29% and 33%) by weight.
• Another embodiment of the present invention is a sitagliptin tannate complex wherein the ratio of sitagliptin to tannic acid is about 3 : 1 to about 1 :4 by weight; for example about 1 :2 by weight.
• Another embodiment of the present invention is a pharmaceutical composition
• a pharmaceutical composition comprising a therapeutically effective amount of the sitagliptin tannate complex according to claim 1 and an inert carrier.
• Another embodiment of the present invention is a pharmaceutical composition
• a pharmaceutical composition comprising a therapeutically effective amount of the sitagliptin tannate complex according to claim 1 , a therapeutically effective amount of at least one additional pharmaceutically active ingredient (e.g., a biguanide such as metformin or a pharmaceutically acceptable salt thereof) and an inert carrier.
• a therapeutically effective amount of the sitagliptin tannate complex according to claim 1 a therapeutically effective amount of at least one additional pharmaceutically active ingredient (e.g., a biguanide such as metformin or a pharmaceutically acceptable salt thereof) and an inert carrier.
• Another embodiment of the present invention is a pharmaceutical intermediate, which comprises a pharmaceutically effective amount of a sitagliptin tannate complex, a
• pharmaceutically acceptable polymer e.g., polyethylene glycol (PEG), such as PEG 3350, PEG 6000 or PEG 8000
• pharmaceutically acceptable polyols e.g., mannitol or maltitol
• high intensity sweeteners e.g., sucralose
• flavorants e.g., mint, cherry or banana flavor
• an oral dosage form e.g. a tablet, capsule, pellet or powder
• the pharmaceutical intermediate comprising a therapeutically effective amount of a sitagliptin tannate complex.
• Another embodiment of the present invention is an oral dosage form, which comprises the pharmaceutical intermediate comprising a therapeutically effective amount of a sitagliptin tannate complex and the oral dosage form is in the form of a soft chew, medicated gum, chewable tablet, disintegrating tablet, syrup, sachet, oral film, gel or lyosphere.
• an oral dosage form e.g., a soft chew, medicated gum, oral film, disintegrating tablet or syrup
• the pharmaceutical intermediate comprising a therapeutically effective amount of a sitagliptin tannate complex, wherein the sitagliptin has negligible release in the mouth and immediate release in the stomach.
• Another embodiment of the present invention is a method for treating, controlling or preventing of one or more diseases for which an inhibitor of DPP-IV is indicated comprising the administration a therapeutically effective amount of the sitagliptin tannate complex to a patient in need thereof.
• Another embodiment of the present invention is a method for treating, controlling or preventing type 2 diabetes, obesity and high blood pressure comprising the administration of a therapeutically effective amount of the sitagliptin tannate complex to a patient in need thereof.
• Another embodiment of the present invention is the use of a sitagliptin tannate complex for the manufacture of a medicament for the treatment and/or prevention of one or more diseases for which an inhibitor of DPP-IV is indicated.
• “Mammal” includes humans and other mammalian animals.
• terapéuticaally effective amount is intended to mean that amount of a pharmaceutically active ingredient that will elicit the biological or medical response of a tissue or a system, animal or human, that is being sought by a researcher, veterinarian, medical doctor or other clinician (e.g., inhibiting DPP-IV).
• a "prophylactically effective amount” is intended to mean that amount of a pharmaceutical drug that will prevent or reduce the risk of occurrence of the biological or medical event that is sought to be prevented in a tissue, a system, animal or human by a researcher, veterinarian, medical doctor or other clinician.
• preventing or "prevention” are used herein to refer to administering a compound before the onset of clinical symptoms.
• immediate release means that at least 85% of the drug is released from the dosage form within 120 minutes or less when tested in a USP type 2 apparatus in a fasted state simulated intestinal fluid (FaSSIF) at a pH of 6.5 at room temperature (approximately 25 C), which can be made using SIFTM powder (from biorelevant.com Ltd) as follows:
• non-ligible release means that the amount of sitagliptin dissociated from the sitagliptin tannate complex is not sufficient for the sitagliptin tannate complex to lose its tastemasking activity in a subject; e.g., up to 10% of the sitagliptin is dissociated from the sitagliptin tannate complex, up to 5% of the sitagliptin is dissociated from the sitagliptin tannate complex, or up to 3% of the sitagliptin is dissociated from the sitagliptin tannate complex.
• composition is intended to encompass both bulk
• compositions and individual dosage units comprised of more than one (e.g., two)
• pharmaceutically active agents such as, for example, the sitagliptin tannate complex and an additional active ingredient.
• examples of other pharmaceutically active ingredients that may be administered in combination with the sitagliptin tannate complex of the present invention, and either administered separately or in the same pharmaceutical composition, include, but are not limited to:
• insulin sensitizers including (i) PPARy agonists such as the glitazones (e.g. troglitazone, pioglitazone, englitazone, MCC-555, rosiglitazone, and the like) and other PPAR ligands, including PPAR ⁇ / ⁇ dual agonists, such as KRP-297, and PPARa agonists such as fenofibric acid derivatives (gemfibrozil, clofibrate, fenofibrate and bezafibrate), (ii) biguanides such as metformin HC1 and phenformin, and (iii) protein tyrosine phosphatase- IB (PTP-1B) inhibitors;
• PPARy agonists such as the glitazones (e.g. troglitazone, pioglitazone, englitazone, MCC-555, rosiglitazone, and the like
• a-glucosidase inhibitors such as acarbose
• glucagon receptor antagonists such as those disclosed in WO 98/04528, WO 99/01423, WO 00/39088, and WO 00/69810;
• GLP-1, GLP-1 mimetics, and GLP-1 receptor agonists such as those disclosed in WO00/42026 and WO00/59887;
• PACAP PACAP, PACAP mimetics, and PACAP receptor 3 agonists such as those disclosed in WO 01/23420;
• cholesterol lowering agents such as (i) HMG-CoA reductase inhibitors (lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rivastatin, itavastatin, rosuvastatin, and other statins), (ii) sequestrants (cholestyramine, colestipol, and dialkylaminoalkyl derivatives of a cross-linked dextran), (iii) nicotinyl alcohol, nicotinic acid or a salt thereof, (iv) PPAR ⁇ agonists such as fenofibric acid derivatives (gemfibrozil, clofibrate, fenofibrate and bezafibrate), (v) PPAR ⁇ / ⁇ dual agonists, such as KRP-297, (vi) inhibitors of cholesterol absorption, such as beta-sitosterol and ezetimibe, (vii) acyl CoAxhol
• anti-obesity compounds such as fenfluramine, dexfenfluramine, phentermine, sibutramine, orlistat, neuropeptide Y5 inhibitors, and ⁇ adrenergic receptor agonists;
• agents intended for use in inflammatory conditions such as aspirin, nonsteroidal anti-inflammatory drugs, glucocorticoids, azulfidine, and cyclo-oxygenase 2 selective inhibitors.
• the above combinations include combinations of the sitagliptin tannate complex of the present invention not only with one other pharmaceutically active ingredient, but also with two or more different pharmaceutically active ingredients.
• Non-limiting examples include combinations of the sitagliptin tannate complex with two or more pharmaceutically active ingredients selected from biguanides, sulfonylureas, HMG-CoA reductase inhibitors, PPAR agonists, PTP-1B inhibitors, other DPP-IV inhibitors, and anti-obesity compounds.
• the bulk composition and each individual dosage unit can contain fixed amounts of the afore-said "more than one pharmaceutically active agents".
• the bulk composition is material that has not yet been formed into individual dosage units.
• An illustrative dosage unit is an oral dosage unit such as tablets, pills and the like.
• the herein-described method of treating a patient by administering a pharmaceutical composition of the present invention is also intended to encompass the administration of the afore-said bulk composition and individual dosage units.
• Oral dosages of the present invention when used for the indicated effects, will range between about 0.01 mg per kg of body weight per day (mg/kg/day) to about 100 mg/kg/day, preferably 0.01 to 10 mg/kg/day, and most preferably 0.1 to 5.0 mg/kg/day.
• compositions are preferably provided in the form of oral dosage forms containing 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 200, and 500 milligrams of sitagliptin for the symptomatic adjustment of the dosage to the patient to be treated.
• a medicament typically contains from about 0.01 mg to about 500 mg of sitagliptin, preferably, from about 1 mg to about 200 mg of active ingredient.
• the sitagliptin tannate complex can form the active pharmaceutical ingredient, and are typically administered in admixture with suitable
• carrier materials
• carrier suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.
• the active pharmaceutical ingredient can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the active pharmaceutical ingredient can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
• an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like
• any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
• Additional pharmaceutical adjuvants include binders, lubricants, sweeteners, flavoring agents, disintegrating agents and coloring agents, which are known in the art (see, e.g.,
• Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
• Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
• Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
• sitagliptin tannate complex of the present invention can be made by the following process:
• step (3) Wash the residue obtained in step (2) with a polar pharmaceutically acceptable liquid (e.g., water);
• a polar pharmaceutically acceptable liquid e.g., water
• step (4) Dry the residue obtained in step (4), for example, in a vacuum oven (e.g. at 50°C) for about 3 to 10 hours, to provide the sitagliptin tannate complex;
• the active solution of sitagliptin was prepared by dissolving 0.5 g of sitagliptin freebase in 20 ml of methanol. 1 g of tannic acid was dissolved in the same amount of methanol to form tannic acid dispersion. The sitagliptin solution was then added slowly to tannic acid dispersion while stirring. The mixture was allowed to stir until all the solvent evaporated under ambient conditions in a fume hood. The solid material formed was pulverized into powder. 100 ml of water was added to the powder and the mixture stirred for 30 minutes, before centrifuging at 15K rpm to remove the liquid. The washed sitagliptin tannate complex was then dried in a constant temperature oven at 50 °C.
• Stage 1 A sample of sitagliptin tannate complex of Example 1 or 2 was placed in 10 mL of SSF, which was prepared by dissolving 8.0 g of NaCl, 0.19 g of potassium phosphate monobasic, and 2.38 g of sodium phosphate dibasic in 1 L of water, and adjusting to pH 6.8 with phosphoric acid, heated to 37 °C, for 1 minute and an aliquot was removed.
• Stage 2 The remaining solution transferred to 500 mL of SGF, which was prepared by dissolving 2.0 g of NaCl in 1 L of water, and adding 1.4 mL of concentrated hydrochloric acid.
• SGF was stirred at 37 °C with apparatus 2 (paddles), and aliquots were collected at 6 time- points.
• Fig. 1 depicts the dissolution profile of Example 1
• Fig. 2 depicts the dissolution profile of Example 2.
• Both profiles indicate that very little to no sitagliptin was released in SSF. This indicates that the sitagliptin-tannic acid complex is not soluble or almost not soluble at neutral pH and, hence, a subject would not be expected to taste the unpleasant flavor of sitagliptin. However, in both profiles, the sitagliptin is rapidly released from the complex at the low pH of SGF and, therefore, would be expected to be available for absorption by the subject.
• sitagliptin tannate complexes obtained in Examples 1 and 2 were formulated as a soft chew by incorporating the sitagliptin tannate complex of the following composition:
• the soft chew formulation was prepared as follows:
• part A The ingredients of part A were mixed until uniform;
• step (2) The mixed ingredients from step (2) were melted and added to the mixed ingredients of step (1) and mixed well;
• step (3) The mixed ingredients from step (3) were added to the mixed ingredient from step (4) and mixed until uniform;

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Diabetes (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Emergency Medicine (AREA)
• Molecular Biology (AREA)
• Physiology (AREA)
• Nutrition Science (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Zoology (AREA)
• Endocrinology (AREA)
• Biophysics (AREA)
• Child & Adolescent Psychology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (11)

Applications Claiming Priority (2)

Publications (1)

Family

ID=54324454

Family Applications (1)

Country Status (12)

Cited By (2)

Families Citing this family (1)

Citations (21)

Family Cites Families (6)

• 2015
  • 2015-04-13 JP JP2016562508A patent/JP6523328B2/ja active Active
  • 2015-04-13 MX MX2016013588A patent/MX374598B/es active IP Right Grant
  • 2015-04-13 BR BR112016023839A patent/BR112016023839A8/pt not_active Application Discontinuation
  • 2015-04-13 ES ES15780045T patent/ES2932383T3/es active Active
  • 2015-04-13 US US15/302,211 patent/US9833463B2/en active Active
  • 2015-04-13 CA CA2945681A patent/CA2945681A1/en not_active Abandoned
  • 2015-04-13 KR KR1020167028345A patent/KR102351813B1/ko active Active
  • 2015-04-13 EP EP15780045.9A patent/EP3131631B1/en active Active
  • 2015-04-13 AU AU2015247921A patent/AU2015247921B2/en active Active
  • 2015-04-13 WO PCT/US2015/025504 patent/WO2015160678A1/en not_active Ceased
  • 2015-04-13 CN CN201580020211.4A patent/CN106456998B/zh active Active
  • 2015-04-13 RU RU2016144695A patent/RU2696588C2/ru active

Patent Citations (21)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events